The White House issued an Executive Order aimed at accelerating development and access for psychedelic-based treatments, outlining potential prioritization of FDA review for Breakthrough-designated programs, expanded access pathways, new federal funding to support state implementation, tighter coordination among HHS, FDA, and VA, and timely post-approval rescheduling. Helus Pharma, operating as Cybin, positioned itself squarely within that policy lane, highlighting HLP003, a Phase 3 adjunctive therapy for major depressive disorder with FDA Breakthrough Therapy designation, and HLP004 in Phase 2 for generalized anxiety disorder.
The policy move signals a shift from permissive research to building an operational framework for delivery at scale. For sponsors, the prospect of prioritized review and clearer rescheduling expectations reduces friction created by Schedule I handling and post-approval uncertainty, potentially lowering capital risk for late-stage programs. For Helus, the timing validates a focus on novel serotonergic agonists rather than repurposed classical compounds and points to a path where VA partnerships, pragmatic trials, and structured expanded access could become meaningful components of development and adoption. None of this, however, shortcuts the evidentiary burden around durability, functional outcomes, and reproducibility across care settings.
Executionally, sites could see near-term investment to stand up psychedelic-capable infrastructure: controlled dispensing, observation suites, therapist co-treatment models, and fidelity monitoring. Expanded access may broaden patient reach but will compete with recruitment for randomized trials; sponsors will need to recalibrate site mix, timelines, and inclusion strategies to avoid enrollment drag. CROs and vendors can expect demand for therapist training at scale, therapy-session fidelity tools, blinded assessment workflows that account for noticeable psychoactive effects, and centralized drug accountability systems suited to higher-scrutiny chain-of-custody. While dosing remains in-clinic, remote pre- and post-session assessments and safety follow-up create space for hybrid models, leveraging digital symptom capture and suicidality monitoring without diluting protocol control.
Regulatory operations still carry unresolved questions. Prioritization for Breakthrough programs may compress timelines, but study designs must contend with expectancy bias, choice of control (including active comparators), and strategies to safeguard rater blinding. Sponsors should anticipate heightened emphasis on validated functional endpoints and longer-term relapse prevention data, alongside formal therapy-component standardization that could be addressed via REMS-like requirements. CMC and scheduling constraints remain binding prior to approval; the Order’s call for “timely” rescheduling requires alignment with DEA processes that historically introduce variability. Coordinated HHS-FDA-VA activity could, however, open pathways for large, uniform networks and payer-relevant evidence, especially if the VA operationalizes pilots and pragmatic studies linked to real-world outcomes.
For Helus and peers, the near-term opportunity is to convert policy momentum into operational readiness: therapist supply chains, site accreditation, and protocol designs that withstand regulatory scrutiny while meeting payer thresholds. Watch for concrete agency deliverables: guidance on psychotherapy credentialing and fidelity, specifics on expanded access eligibility and data capture, interagency timelines for rescheduling, and any VA procurement and data-sharing frameworks that could anchor scale deployment. On the company side, HLP003’s Phase 3 execution, safety management, and durability signals will dictate whether prioritized review meaningfully advances timelines. The risks are equally clear: expanded access siphoning trial-eligible patients, divergence between regulators on therapy standardization, persistent workforce shortages at sites, and manufacturing scale-up for controlled substances. Over the next 12 months, the tell will be whether IND amendments, site activations, and review queues actually move faster—and whether sponsors can translate that speed into clean, regulator-ready data and implementable care models.
HLP003: the facts in one place
- Also written: CYB003, deupsilocin, psilocin-d10
- Sponsor: Helus Pharma (formerly Cybin Inc.)
- Mechanism: deuterated serotonergic agonist targeting the 5-HT2A receptor
- Indication studied: adjunctive treatment of Major Depressive Disorder (MDD)
- Phase: Phase 3
- Enrollment: 223
- Primary endpoint: change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) at Day 42
- Headline result: Phase 2: approximately 23-point reduction in MADRS score at 12 months after two doses; 100% response rate and 71% remission rate
- Registry identifier: not publicly listed
- Current status: Phase 3 PARADIGM program ongoing; APPROACH study completed enrollment July 2026; NDA filing expected 2028
- APPROACH study enrollment completed: July 2026
- APPROACH topline data anticipated: Q4 2026
- NDA filing expected: 2028
- FDA Breakthrough Therapy Designation: date not specified in summary
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
